Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that CD117 + status confers therapeutic sensitivity to Imatinib in patients with Gastrointestinal Stromal Tumor.
The European Medicines Agency (EMA) has authorized imatinib for the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD 117) positive gastrointestinal stromal tumors (GIST). Patients who have a low or very low risk of recurrence should not received adjuvant treatment.
This statement is based on a regulatory approval from the European Medicines Agency:
Glivec is indicated for the treatment of the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment.